Orlistat, short-term use phentermine (≤12 weeks), phentermine-topiramate, naltrexone-bupropion, high-dosed liraglutide and semaglutide, both GLP-1 analogues, and tirzepatide, a dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, have been approved by the FDA for adult obesity treatment. The gene discussed is GIP; the disease is obesity due to melanocortin 4 receptor deficiency.